News and Events
Sharing Stories of
Patients, Employees
and Communities
Featured News
January 18, 2022
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 06, 2022
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
November 19, 2021
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
Our Commitment to Responsibility
Corporate responsibility has always played a central role in our business and has proven even more critical during the past year as we faced some of the most pressing public health and societal issues of our time – a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our recently published Corporate Responsibility Report expounds on these efforts.
Cancer Trials At-a-Glance
Learn more about our ongoing clinical research program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across clinical trials evaluating intravenous and subcutaneous dosing.
Unlocking IL-2's Potential
As the unmet medical need in oncology changes, Alkermes is using its R&D capabilities honed over 30 years of work on complex diseases to investigate a potential next breakthrough in cancer therapy.
Media Resources
Company Description
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.
Follow us on our social channels
